RecruitingNCT04347187

REGistry of Long-term AnTithrombotic TherApy-2

Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation


Sponsor

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Enrollment

2,000 participants

Start Date

Jan 15, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Documented atrial fibrillation with CHA2DS2VASC \> 1

Exclusion Criteria1

  • Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention

Interventions

DRUGAnticoagulants

oral anticoagulants, dual or triple antithrombotic theraphy


Locations(1)

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Moscow, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04347187


Related Trials